Insulin therapy and body weight: benefits of biphasic human insulin analogue NovoMix 30
Body weight (BW) excess is a characteristic problem for type 2 diabetes mellitus (T2DM) both as its pathogenetic feature and as a side effect of blood glucose lowering therapy. In the latter case reduction of glycosuria and frequent hypoglycemic events are primarily blamed for BW gain, but additiona...
Guardado en:
Autor principal: | Elena Viktorovna Surkova |
---|---|
Formato: | article |
Lenguaje: | EN RU |
Publicado: |
Endocrinology Research Centre
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f7819690429c457ab589d052cfd31b4b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Therapy with biphasic insulin aspart 30/70 (NovoMix 30) improves glycemic control in patients with type 2 diabetes mellitus: resultsfrom a Russian cohort of IMPROVE observational program designed to study safety and efficiency of biphasic insulin aspart 30 inroutine clinical practice
por: Marina Vladimirovna Shestakova, et al.
Publicado: (2010) -
IMPROVE observational program: safety and effectiveness of biphasic insulin aspart 30 in routine clinical practice. Overview of starting characteristics of the Russian patient cohort
por: Marina Vladimirovna Shestakova, et al.
Publicado: (2009) -
Ten years of NovoMix 30 in Russian and international clinical practice
por: Elena Viktorovna Surkova
Publicado: (2013) -
Insulin degludec/insulin aspart is the first co-formulation of basal and prandial insulin analogues
por: Ivan Ivanovich Dedov, et al.
Publicado: (2014) -
Effects of metformin on body weight in patients with type 2 diabetes mellitus,receiving insulin analogue treatment
por: Tatiana Ivanovna Romantsova, et al.
Publicado: (2013)